Home Sleep Therapy for Older Adults With MCI
NCT05771844
Recruiting
The goal of this clinical trial is to learn about the ability of non-invasive brain stimulation during sleep to enhance people's deep sleep and its potential benefit on memory in people with mild cognitive impairment via home use sleep therapy device (SleepWISP) as well as learn about biomarkers associated with Alzheimer disease (AD). The clinical trial aims to answer the following main questions: 1. Whether the non-invasive transcranial electrical stimulation (TES) delivered by SleepWISP could... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
02/14/2025
Locations: Wake Forest University, Winston-Salem, North Carolina +1 locations
Conditions: Mild Cognitive Impairment, Sleep, Transcranial Electrical Stimulation, Machine Learning, Memory
Register for Updates
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT06109441
Recruiting
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, and a Maintenance Phase. Eligible subjects will be enrolled to receive a SC loading dose of ALTB-268 followed by weekly doses of ALTB-268 for 12 weeks. Primary efficacy endpoint will be evaluated at week 12. Week 12 dosing will occur during the 40 wks Ma... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/14/2025
Locations: San Diego Gastroenterology, San Diego, California +23 locations
Conditions: Ulcerative Colitis
Register for Updates
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
NCT06325046
Recruiting
This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the body (localized). ART is a type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose. I... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota +4 locations
Conditions: Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Register for Updates
Alcohol-focused Support of Survivors in Sororities Training (ASSIST) - Pilot
NCT06570720
Recruiting
The goal of this clinical trial is to conduct a preliminary evaluation of the ASSIST (Alcohol-focused Support of Survivors in Sororities Training) intervention in sorority chapters. ASSIST is a newly developed web-based intervention to increase peer support of sexual assault survivors and reduce encouragement of drinking to cope within social networks of sororities. To test whether the intervention is feasible and shows preliminary signs of working, a pilot cluster randomized trial will be condu... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: University of Washington, Seattle, Washington
Conditions: Alcohol Drinking in College
Register for Updates
A U.S. Double-blind, Placebo-controlled Phase 2 Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder
NCT06809179
Recruiting
This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2025
Locations: Vistagen Clinical Site, Largo, Florida +2 locations
Conditions: Social Anxiety Disorder
Register for Updates
Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy
NCT03487185
Recruiting
A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: University of Alabama - Birmingham, Birmingham, Alabama +13 locations
Conditions: Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
Register for Updates
Mindfulness in the OR
NCT04515667
Recruiting
The purpose of this research study is to understand the effect of a short mindfulness video on self perceived performance in the OR. Specifically, assessing the effectiveness of brief mindfulness intervention on physician focus, anxiety and perceived performance at the time of a procedure through a survey containing a modified flow state scale and modified applied mindfulness process scale
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Performance at Work
Register for Updates
Pragmatic Trial of Remote TDCS and Somatosensory Training for Phantom Limb Pain with Machine Learning to Predict Treatment Response
NCT05188183
Recruiting
The investigators have designed a pragmatic trial of home-based transcranial direct current stimulation (tDCS) for phantom limb pain (PLP), the PLP-EVEREST trial (PLP-EffectiVEness pRagmatic Stimulation Trial) to test a portable device that would reach underrepresented populations and would validate this therapy in a more pragmatic setting. Subjects will be randomized to home-based tDCS of the primary motor cortex (M1) with somatosensory training or usual care only (including their current pharm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Spaulding Hospital Cambridge, Cambridge, Massachusetts
Conditions: Phantom Limb Pain
Register for Updates
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
NCT05584722
Recruiting
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify... Read More
Gender:
ALL
Ages:
Between 15 years and 80 years
Trial Updated:
02/14/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
Register for Updates
Study of Ribociclib and Everolimus in HGG and DIPG
NCT05843253
Recruiting
The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target. The main question the study aims to answer is whether the combination of ribociclib and everolimus can prolong the life of patients diagnosed with HGG, including DIPG.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
02/14/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +17 locations
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +98 locations
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults with Social Anxiety Disorder (PALISADE-3)
NCT06358651
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2025
Locations: Vistagen Clinical Site, Phoenix, Arizona +18 locations
Conditions: Social Anxiety Disorder
Register for Updates